VF
KROS icon

Virtu Financial’s Keros Therapeutics KROS Stock Holding History

Virtu Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,708
Closed -$350K – 1604
2023
Q2 		$350K Buy
+8,708
New +$382K 0.03% 544
2021
Q3 		– Sell
-5,144
Closed -$218K – 1736
2021
Q2 		$218K Buy
+5,144
New +$279K 0.02% 940

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Virtu Financial's KROS Position: Q3 2023 in Review

Virtu Financial sold out of Keros Therapeutics (KROS) in Q3 2023, closing a stake of 8,708 shares — an estimated $350K sold.

Virtu Financial first reported a position in KROS in Q2 2021 and held it in 2 quarters. The position peaked at $350K in Q2 2023. 107 funds tracked by Wall St. Rank hold KROS as of Q3 2023.

  • Virtu Financial reported no remaining Keros Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Virtu Financial sold 8,708 Keros Therapeutics shares in Q3 2023, an estimated $350K.
  • Virtu Financial first reported a position in Keros Therapeutics in Q2 2021 and held it in 2 quarters.
  • Virtu Financial's Keros Therapeutics position peaked at $350K in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.